Work

1876P Effectiveness of maintenance therapy with pembrolizumab vs pemetrexed and pembrolizumab in advanced non-small cell lung cancer: Real-world data from the German prospective CRISP registry (AIO-TRK-0315)

Year: 2025

Type: article

Study design: Observational Study

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2025.08.2500

Authors: S. Heinzen, M. Groschek, S. Dörfel, J.K. Schröder, A. Fleitz, S. Zacharias, A. Härzschel, C. Lennartz, A. Groth, P. Ludwig, M. De Wit, J.K. Kern, F. Griesinger, M. Thomas, W.E.E. Eberhardt, M. Sebastian

Institutions: Goethe University Frankfurt, University Hospital Frankfurt, AIO Studien gGmbH, Vivantes Klinikum, Klinikum Würzburg Mitte, Pius Hospital Oldenburg, Frankfurt Cancer Institute

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Amgen, Eli Lilly and Company, Pfizer, AstraZeneca, Sanofi, Gilead Sciences, Ariad Pharmaceuticals, Celgene, Regeneron Pharmaceuticals, Les Laboratories Pierre Fabre, KWF Kankerbestrijding, Daiichi Sankyo Europe

OpenAlex ID: W4415939743

FWCI:

Cites:

Cited by:

Related to: 10